144 related articles for article (PubMed ID: 3966916)
21. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
Fonne-Pfister R; Meyer UA
Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
[TBL] [Abstract][Full Text] [Related]
22. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
Haefeli WE; Bargetzi MJ; Follath F; Meyer UA
J Cardiovasc Pharmacol; 1990 May; 15(5):776-9. PubMed ID: 1692938
[TBL] [Abstract][Full Text] [Related]
23. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.
Dayer P; Gasser R; Gut J; Kronbach T; Robertz GM; Eichelbaum M; Meyer UA
Biochem Biophys Res Commun; 1984 Nov; 125(1):374-80. PubMed ID: 6508804
[TBL] [Abstract][Full Text] [Related]
25. Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation.
Matsunaga E; Zeugin T; Zanger UM; Aoyama T; Meyer UA; Gonzalez FJ
J Biol Chem; 1990 Oct; 265(28):17197-201. PubMed ID: 1976628
[TBL] [Abstract][Full Text] [Related]
26. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
27. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Jacqz-Aigrain E; Gueguen M; Zanger UM; Robieux I; Alvarez F
Biochem Pharmacol; 1991 Jun; 41(11):1657-63. PubMed ID: 2043154
[TBL] [Abstract][Full Text] [Related]
29. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.
Kahn GC; Boobis AR; Murray S; Brodie MJ; Davies DS
Br J Clin Pharmacol; 1982 May; 13(5):637-45. PubMed ID: 7082530
[TBL] [Abstract][Full Text] [Related]
30. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
[TBL] [Abstract][Full Text] [Related]
31. Effects of nortriptyline on the activities of human and rat liver microsome bufuralol 1'-hydroxylase in vitro.
Tu ZG; Seddon CE; Boobis AR; Davies DS
Zhongguo Yao Li Xue Bao; 1989 Sep; 10(5):465-9. PubMed ID: 2618737
[TBL] [Abstract][Full Text] [Related]
32. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
33. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.
Dayer P; Leemann T; Striberni R
Clin Pharmacol Ther; 1989 Jan; 45(1):34-40. PubMed ID: 2910636
[TBL] [Abstract][Full Text] [Related]
34. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.
Kobayashi S; Murray S; Watson D; Sesardic D; Davies DS; Boobis AR
Biochem Pharmacol; 1989 Sep; 38(17):2795-9. PubMed ID: 2775304
[TBL] [Abstract][Full Text] [Related]
35. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS; Tucker GT; Woods HF
Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
[TBL] [Abstract][Full Text] [Related]
36. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
[TBL] [Abstract][Full Text] [Related]
37. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.
Fonne-Pfister R; Bargetzi MJ; Meyer UA
Biochem Biophys Res Commun; 1987 Nov; 148(3):1144-50. PubMed ID: 3500719
[TBL] [Abstract][Full Text] [Related]
38. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6.
Penman BW; Reece J; Smith T; Yang CS; Gelboin HV; Gonzalez FJ; Crespi CL
Pharmacogenetics; 1993 Feb; 3(1):28-39. PubMed ID: 8485585
[TBL] [Abstract][Full Text] [Related]
40. Polymorphism of human cytochrome P-450.
Guengerich FP; Umbenhauer DR; Churchill PF; Beaune PH; Böcker R; Knodell RG; Martin MV; Lloyd RS
Xenobiotica; 1987 Mar; 17(3):311-6. PubMed ID: 3577206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
